Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  GenSight Biologics    SIGHT   FR0013183985

GENSIGHT BIOLOGICS

(SIGHT)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
07/17/2019 07/18/2019 07/19/2019 07/22/2019 07/23/2019 Date
1.676(c) 1.602(c) 1.684(c) 1.88(c) 1.852 Last
215 285 83 382 190 935 624 822 310 026 Volume
-2.56% -4.42% +5.12% +11.64% -1.49% Change
More quotes
Financials (EUR)
Sales 2019 7,10 M
EBIT 2019 -26,6 M
Net income 2019 -26,6 M
Finance 2019 1,80 M
Yield 2019 -
Sales 2020 23,8 M
EBIT 2020 -20,0 M
Net income 2020 -21,5 M
Debt 2020 10,5 M
Yield 2020 -
P/E ratio 2019 -2,04x
P/E ratio 2020 -2,46x
EV / Sales2019 7,33x
EV / Sales2020 2,71x
Capitalization 53,9 M
More Financials
Company
GenSight Biologics specializes in the research and development of gene therapies for the treatment of mitochondrial diseases and eye neurodegeneratives. At the end of 2017, the company had a portfolio of 2 products, including 1 in phase III clinical development (GS010 for the treatment of Leber... 
More about the company
Surperformance© ratings of GenSight Biologics
Trading Rating : Investor Rating : -
More Ratings
Latest news on GENSIGHT BIOLOGICS
07/11GENSIGHT BIOLOGICS : completes enrollment of GS010 REFLECT Phase III trial in th..
PU
06/19GENSIGHT BIOLOGICS : Announces Presentation of Results from the REVERSE Phase II..
AQ
05/28GENSIGHT BIOLOGICS : Corporate presentation, May 2019
PU
05/21GENSIGHT BIOLOGICS : BALO prior notification
PU
05/21GENSIGHT BIOLOGICS : Explanatory Statement – 2019 General Meeting
PU
05/21GENSIGHT BIOLOGICS : Nominees to the Board of Directors
PU
05/21GENSIGHT BIOLOGICS : Annual General Meeting on June 11, 2019
PU
05/21GENSIGHT BIOLOGICS : Notice of General Meeting on June 11, 2019
PU
05/18GENSIGHT BIOLOGICS : reports positive results from GS010 trial for LHON treatmen..
AQ
05/07GENSIGHT BIOLOGICS : Corporate presentation, April 2019
PU
More news
Sector news : Bio Therapeutic Drugs
07/22GILEAD SCIENCES : Says Study of GS-6207 Showed HIV Capsid Inhibition Can Lead Vi..
DJ
07/22GILEAD SCIENCES : Licenses Durect's Saber Technology for Injectable HIV Product
DJ
07/19Gilead Licenses Respiratory, Herpes Antiviral Research Programs From Novartis
DJ
07/17GILEAD SCIENCES : Chief Scientific Officer John McHutchison to Leave
DJ
07/16As steep patent cliff looms, Shionogi moves to develop its own U.S. sales sta..
RE
More sector news : Bio Therapeutic Drugs
Chart GENSIGHT BIOLOGICS
Duration : Period :
GenSight Biologics Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENSIGHT BIOLOGICS
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 5,05  €
Last Close Price 1,88  €
Spread / Highest target 379%
Spread / Average Target 169%
Spread / Lowest Target 6,38%
EPS Revisions
Managers
NameTitle
Bernard Jacques Alex Gilly Chief Executive Officer & Director
Michael S. Wyzga Independent Chairman
Thomas Gidoin Chief Financial Officer
Barrett Katz Chief Medical Officer
Harvey N. Masonson Vice President-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
GENSIGHT BIOLOGICS-43.54%60
GILEAD SCIENCES3.77%82 702
VERTEX PHARMACEUTICALS5.05%44 598
REGENERON PHARMACEUTICALS-20.61%32 544
GENMAB14.24%11 908
SAREPTA THERAPEUTICS INC32.61%11 068